Trial site
Anyang People's Hospital
Anyang, Henan 455000, ChinaNot linked to an institution yet
- 11running trials
- 4closed trials
The trials here
What the 15 trials at this site are about, from their registry records.
- Phase
- Phase 25 trials
- Phase 35 trials
- Phase 1/22 trials
- Phase 41 trial
- Status
- Not yet recruiting7 trials
- Completed4 trials
- Recruiting3 trials
- Active, not recruiting1 trial
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.5 trials
- Capital Medical University2 trials
- Nanjing RegeneCore Biotech Co., Ltd.2 trials
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.1 trial
- Sichuan Academy of Medical Sciences1 trial
- and 4 more
Running trials
Recruiting
Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL-2)
NCT07800572· Phase 2· Capital Medical University· Source
Contact: Xunming Ji, PhD/MD
Not yet recruiting
Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response
NCT07797231· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: fangjie chen, Bachelor
Recruiting
A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus
NCT07509892· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Xiao hu Wang, Master
Recruiting
Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke
NCT07509645· Phase 3· Capital Medical University· Source
Contact: Jiangang Zhang
Recruiting
Phase II Trial of RC1416 Injection in Asthma
NCT07403487· Phase 2· Nanjing RegeneCore Biotech Co., Ltd.· Source
Contact: Jia Ming Yong
Recruiting
Phase II Study of RC1416 Injection in COPD
NCT07402551· Phase 2· Nanjing RegeneCore Biotech Co., Ltd.· Source
Contact: Mingyong Jia
Recruiting
A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
NCT07367529· Phase 1/2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Minyong Jia, Master
Recruiting
Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients
NCT07266116· Phase 1/2· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Contact: Zhengrong Liu, Master
Not yet recruiting
A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults
NCT07083739· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Zhengrong Liu, Doctor
Recruiting
A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia
NCT06900920· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Zhengrong Liu, Doctor
Active, not recruiting
SIM0718 Treatment of Asthma Clinical Study
NCT06488755· Phase 3· Simcere Pharmaceutical Co., Ltd· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error